Literature DB >> 30143565

Myasthenia gravis following alemtuzumab therapy for multiple sclerosis.

Luciana Midaglia1, Margarida Gratacòs2, Edoardo Caronna2, Nuria Raguer2, Jaume Sastre-Garriga2, Xavier Montalban2, Mar Tintoré2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30143565      PMCID： PMC6161544          DOI： 10.1212/WNL.0000000000006251

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  9 in total

1.  Development of myasthenia gravis in a patient with multiple sclerosis during treatment with glatiramer acetate.

Authors:  A Frese; F Bethke; P Lüdemann; F Stögbauer
Journal:  J Neurol       Date:  2000-09       Impact factor: 4.849

2.  Development of myasthenia gravis in two patients with multiple sclerosis following interferon beta treatment.

Authors:  J Dionisiotis; Y Zoukos; T Thomaides
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-07       Impact factor: 10.154

3.  Myasthenia gravis and multiple sclerosis: an uncommon presentation.

Authors:  Paulo J Lorenzoni; Rosana H Scola; Cláudia S Kamoi Kay; Lineu C Werneck
Journal:  Arq Neuropsiquiatr       Date:  2008-06       Impact factor: 1.420

4.  First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS.

Authors:  Clas Malmeström; Bengt A Andersson; Jan Lycke
Journal:  J Neurol       Date:  2014-08-01       Impact factor: 4.849

5.  Acquired haemophilia A complicating alemtuzumab therapy for multiple sclerosis.

Authors:  Georgia McCaughan; Jennifer Massey; Ian Sutton; Jennifer Curnow
Journal:  BMJ Case Rep       Date:  2017-12-05

6.  Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Authors:  Alasdair J Coles; Cary L Twyman; Douglas L Arnold; Jeffrey A Cohen; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Tamara Miller; Elizabeth Fisher; Rupert Sandbrink; Stephen L Lake; David H Margolin; Pedro Oyuela; Michael A Panzara; D Alastair S Compston
Journal:  Lancet       Date:  2012-11-01       Impact factor: 79.321

Review 7.  A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis.

Authors:  Ruth Ann Marrie; Nadia Reider; Jeffrey Cohen; Olaf Stuve; Per S Sorensen; Gary Cutter; Stephen C Reingold; Maria Trojano
Journal:  Mult Scler       Date:  2014-12-22       Impact factor: 6.312

8.  Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Authors:  Alasdair J Coles; Jeffrey A Cohen; Edward J Fox; Gavin Giovannoni; Hans-Peter Hartung; Eva Havrdova; Sven Schippling; Krzysztof W Selmaj; Anthony Traboulsee; D Alastair S Compston; David H Margolin; Karthinathan Thangavelu; Madalina C Chirieac; Darlene Jody; Panos Xenopoulos; Richard J Hogan; Michael A Panzara; Douglas L Arnold
Journal:  Neurology       Date:  2017-08-23       Impact factor: 9.910

9.  Alopecia Universalis following Alemtuzumab Treatment in Multiple Sclerosis: A Barely Recognized Manifestation of Secondary Autoimmunity-Report of a Case and Review of the Literature.

Authors:  Julian Zimmermann; Timo Buhl; Marcus Müller
Journal:  Front Neurol       Date:  2017-10-30       Impact factor: 4.003
  9 in total
  3 in total

1.  Clinical characteristics of autoimmune disorders in the central nervous system associated with myasthenia gravis.

Authors:  Kimitoshi Kimura; Yoichiro Okada; Chihiro Fujii; Kenichi Komatsu; Ryosuke Takahashi; Sadayuki Matsumoto; Takayuki Kondo
Journal:  J Neurol       Date:  2019-07-24       Impact factor: 4.849

Review 2.  Cross-syndrome: myasthenia gravis and the demyelinating diseases of the central nervous system combination. Systematic literature review and case reports.

Authors:  Ekaterina Luzanova; Svetlana Stepanova; Nikita Nadtochiy; Elena Kryukova; Maria Karpova
Journal:  Acta Neurol Belg       Date:  2022-06-14       Impact factor: 2.396

Review 3.  Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management.

Authors:  Fiammetta Vanoli; Renato Mantegazza
Journal:  Neurotherapeutics       Date:  2022-02-14       Impact factor: 6.088
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.